“We have already demonstrated scientifically that our process and product is exceptional.” Jason Matuszewski, Chief Executive Officer September 26, 2023 BioStem Technologies (OTC: BSEM) has received Investigational Review Board (IRB) approval for a clinical study that will investigate the utilization and effects of its Vendaje Ⓡ wound care product in diabetic foot ulcers. “We have already demonstrated scientifically that our process and product is exceptional. This study will enhance our...
